A federal court in Texas last week found that the Federal Trade Commission likely lacked statutory authority to issue its Non-Compete Clause Final Rule. The court also found the rule was likely arbitrary and capricious because the FTC did not provide sufficient “evidence as to why they chose to impose such a sweeping prohibition — that prohibits entering or enforcing virtually all non-competes — instead of targeting specific, harmful non-competes,” and because the agency failed to consider adequate alternatives to its sweeping final rule. In so doing, the court issued a preliminary injunction against enforcement of the rule only as to the parties challenging the rule (e.g., Ryan LLC, a global tax firm). The court stated that it intends to rule on the ultimate merits of this action on or before Aug. 30. 
 
The AHA last year submitted comments making these and other arguments against the rule. In addition, the AHA and other national organizations in May sent a letter to the FTC requesting a stay on the Sept. 4 effective date to allow for judicial review. 

Related News Articles

Headline
The U.S. Chamber of Commerce Jan. 13 filed a lawsuit against the Federal Trade Commission, saying changes made by the FTC to premerger notification rules under…
Headline
Members of the House Judiciary Committee last week announced an investigation of CVS Caremark for potential practices that could limit patient access to…
Headline
The AHA Nov. 15 filed friend-of-the-court briefs in the U.S. Court of Appeals for the 5th Circuit in support of an earlier denial by the U.S. District Court…
Headline
The AHA, 340B Health, the Minnesota Hospital Association and American Society of Health-system Pharmacists Oct. 4 filed an amicus brief in the U.S. District…
Headline
The AHA filed an amicus brief Oct. 4 in the U.S. Court of Appeals for the 5th Circuit challenging a decision by the U.S. District Court for the Northern…
Headline
A Louisiana district court Sept. 30 upheld a state law prohibiting drug companies from denying Louisiana hospitals 340B discounts for drugs dispensed at…